DSM informs market on the completion of the sale of DSM Sinochem Pharmaceuticals to Bain Capital

Heerlen, NL, 31 Oct 2018 16:00 CET

Royal DSM, a global science-based company in Nutrition, Health and
Sustainable Living, informs its stakeholders that Bain Capital today
has completed the acquisition of DSM Sinochem Pharmaceuticals (DSP),
from DSM and Sinochem Group who each held an equity stake of 50%. The
transaction was announced on 29 June 2018.

DSM received about €250 million for its equity stake, excluding an earn-out (estimated at around €50m) and transaction costs. DSM anticipates a book profit of about €110 million on the transaction to be recognized in Q4 2018. DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs.